{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:20:22Z","timestamp":1791404422060,"version":"4.3.3"},"reference-count":45,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B-cell lymphoma, Richter\u2019s transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, were enrolled. In the dose-escalation phase, patients received 3 to 80 mg\/m2 of selinexor in 3- or 4-week cycles and were assessed for toxicities, pharmacokinetics, and antitumor activity. In the dose-expansion phase, patients were treated with selinexor at 35 or 60 mg\/m2. The most common grade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%). Tumor biopsies showed decreases in cell-signaling pathways (Bcl-2, Bcl-6, c-Myc), reduced proliferation (Ki67), nuclear localization of XPO1 cargos (p53, PTEN), and increased apoptosis after treatment. Twenty-two (31%) of the 70 evaluable patients had an objective responses, including 4 complete responses and 18 partial responses, which were observed across a spectrum of NHL subtypes. A dose of 35 mg\/m2 (60 mg) was identified as the RP2D. These findings suggest that inhibition of XPO1 with oral selinexor at 35 mg\/m2 is a safe therapy with encouraging and durable anticancer activity in patients with R\/R NHL. The trial was registered at www.clinicaltrials.gov as #NCT01607892.<\/jats:p>","DOI":"10.1182\/blood-2016-11-750174","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T01:10:25Z","timestamp":1493860225000},"page":"3175-3183","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":143,"title":["Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"129","author":[{"given":"John","family":"Kuruvilla","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Savona","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Morten","family":"Mau-Sorensen","sequence":"first","affiliation":[{"name":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashat","family":"Gabrail","sequence":"first","affiliation":[{"name":"Gabrail Cancer Institute, Canton, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Garzon","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Savoie","sequence":"first","affiliation":[{"name":"Division of Hematology, University of Calgary, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Flinn","sequence":"first","affiliation":[{"name":"Blood Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Jacoby","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaddeus J.","family":"Unger","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Richard","family":"Saint-Martin","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Rashal","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Friedlander","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Carlson","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kauffman","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Department of Hematology, John Theurer Cancer Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020061111192018200_B1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2020061111192018200_B2","doi-asserted-by":"crossref","first-page":"e106745","DOI":"10.1371\/journal.pone.0106745","article-title":"Rate of primary refractory disease in B and T-cell non-Hodgkin\u2019s lymphoma: correlation with long-term survival","volume":"9","author":"Tarella","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"2020061111192018200_B3","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020061111192018200_B4","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J Exp Med"},{"issue":"28","key":"2020061111192018200_B5","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020061111192018200_B6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2020061111192018200_B7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2020061111192018200_B8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"2020061111192018200_B9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/excr.1999.4672","article-title":"Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function","volume":"253","author":"La\u00edn","year":"1999","journal-title":"Exp Cell Res"},{"issue":"2","key":"2020061111192018200_B10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bjc.2014.260","article-title":"KPT-330 has antitumour activity against non-small cell lung cancer","volume":"111","author":"Sun","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"2020061111192018200_B11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","article-title":"The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation","volume":"2","author":"Culjkovic-Kraljacic","year":"2012","journal-title":"Cell Reports"},{"issue":"4","key":"2020061111192018200_B12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","article-title":"CRM1-mediated nuclear export: to the pore and beyond","volume":"17","author":"Hutten","year":"2007","journal-title":"Trends Cell Biol"},{"issue":"7","key":"2020061111192018200_B13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4161\/cc.8.7.8093","article-title":"The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes","volume":"8","author":"Topisirovic","year":"2009","journal-title":"Cell Cycle"},{"key":"2020061111192018200_B14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2014.03.001","article-title":"Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents","volume":"27","author":"Turner","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"2020061111192018200_B15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci"},{"issue":"23","key":"2020061111192018200_B16","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2020061111192018200_B17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2014.10.003","article-title":"CRM1 as a new therapeutic target for non-Hodgkin lymphoma","volume":"39","author":"Han","year":"2015","journal-title":"Leuk Res"},{"issue":"7","key":"2020061111192018200_B18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin\u2019s lymphomas","volume":"98","author":"Azmi","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2020061111192018200_B19","doi-asserted-by":"crossref","first-page":"e87585","DOI":"10.1371\/journal.pone.0087585","article-title":"Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study","volume":"9","author":"London","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2020061111192018200_B20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2020061111192018200_B21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020061111192018200_B22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020061111192018200_B23","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2020061111192018200_B24","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020061111192018200_B25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/14737140.2015.1009042","article-title":"Emerging drugs for diffuse large B-cell lymphoma","volume":"15","author":"Mondello","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"23","key":"2020061111192018200_B26","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"31","key":"2020061111192018200_B27","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020061111192018200_B28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"30","key":"2020061111192018200_B29","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020061111192018200_B30","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"7","key":"2020061111192018200_B31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"2020061111192018200_B32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020061111192018200_B33","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020061111192018200_B34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"2020061111192018200_B35","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.1999.17.12.3786","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"17","author":"Foss\u00e5","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020061111192018200_B36","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"issue":"34","key":"2020061111192018200_B37","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020061111192018200_B38","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020061111192018200_B39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14712598.2016.1180362","article-title":"Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis","volume":"16","author":"Dada","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"26","key":"2020061111192018200_B40","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020061111192018200_B41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1634\/theoncologist.2015-0227","article-title":"Brentuximab vedotin in transplant-na\u00efve relapsed\/refractory Hodgkin lymphoma: experience in 30 patients","volume":"20","author":"Zinzani","year":"2015","journal-title":"Oncologist"},{"issue":"4","key":"2020061111192018200_B42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2020061111192018200_B43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2020061111192018200_B44","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"2020061111192018200_B45","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/blood.2020007232","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/24\/3175\/1744691\/blood750174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/24\/3175\/1744691\/blood750174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T17:47:17Z","timestamp":1591897637000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/24\/3175\/36283\/Selective-inhibition-of-nuclear-export-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":45,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-11-750174","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2020007232","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]}}}